Literature DB >> 28058492

Severe hepatitis B virus reactivation related to ibrutinib monotherapy.

Yair Herishanu1, Helena Katchman2, Aaron Polliack3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28058492     DOI: 10.1007/s00277-016-2917-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

1.  Comparing Machine Learning Algorithms for Predicting Drug-Induced Liver Injury (DILI).

Authors:  Eni Minerali; Daniel H Foil; Kimberley M Zorn; Thomas R Lane; Sean Ekins
Journal:  Mol Pharm       Date:  2020-06-08       Impact factor: 4.939

Review 2.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 3.  Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Authors:  Georg Maschmeyer; Julien De Greef; Sibylle C Mellinghoff; Annamaria Nosari; Anne Thiebaut-Bertrand; Anne Bergeron; Tomas Franquet; Nicole M A Blijlevens; Johan A Maertens
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

4.  Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.

Authors:  Ying Ni; Lixia Gao; Yan Lu; Shiguang Ye; Lili Zhou; Wenbin Qian; Aibin Liang; Ping Li
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

5.  Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia

Authors:  Gülşen İskender; Dicle İskender; Mustafa Ertek
Journal:  Turk J Haematol       Date:  2020-04-06       Impact factor: 1.831

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.